找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Advances in Cancer Treatment; From Systemic Chemot Iago Dillion Lima Cavalcanti,José Cleberson Santos Book 2021 The Editor(s) (if applicabl

[復(fù)制鏈接]
查看: 45739|回復(fù): 39
樓主
發(fā)表于 2025-3-21 18:12:04 | 只看該作者 |倒序瀏覽 |閱讀模式
期刊全稱Advances in Cancer Treatment
期刊簡稱From Systemic Chemot
影響因子2023Iago Dillion Lima Cavalcanti,José Cleberson Santos
視頻videohttp://file.papertrans.cn/147/146977/146977.mp4
發(fā)行地址Provides comprehensive content on cancer pathophysiology, treatment modalities and antineoplastic chemotherapy in an easy-to-read format.Offers up-to-date information on the target therapies used in c
圖書封面Titlebook: Advances in Cancer Treatment; From Systemic Chemot Iago Dillion Lima Cavalcanti,José Cleberson Santos Book 2021 The Editor(s) (if applicabl
影響因子.This work covers the pathophysiology of cancer, exploring the difficulty of optimal treatment due to the complexity and diversity of cancer types. The search for distinctive molecular biology characteristics of tumor cells is especially relevant in the identification of overexpressed receptors and proteins that can be used as a target for cancer treatment..We highlight the main therapeutic modalities, particularly conventional systemic chemotherapy, addressing its mechanisms of action, therapeutic classes and even the toxic effects. We also describe the main tumor markers, their importance in the diagnosis and treatment of cancer, and the specificity of tumor cells.?..The first chapters serve as an introduction to the central topic of this book, targeted therapy. Key aspects of target therapy, such as classes of drugs, immunotherapy, monoclonal antibodies, checkpoint inhibitors, cancer vaccines and tyrosine kinase inhibitors are presented, and, for each one, the benefits, as well as the adverse effects are reported. Chapter 6 compares conventional systemic chemotherapy and targeted therapy, identifies the risks and benefits and also the eligibility criteria for patient care. The p
Pindex Book 2021
The information of publication is updating

書目名稱Advances in Cancer Treatment影響因子(影響力)




書目名稱Advances in Cancer Treatment影響因子(影響力)學(xué)科排名




書目名稱Advances in Cancer Treatment網(wǎng)絡(luò)公開度




書目名稱Advances in Cancer Treatment網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Advances in Cancer Treatment被引頻次




書目名稱Advances in Cancer Treatment被引頻次學(xué)科排名




書目名稱Advances in Cancer Treatment年度引用




書目名稱Advances in Cancer Treatment年度引用學(xué)科排名




書目名稱Advances in Cancer Treatment讀者反饋




書目名稱Advances in Cancer Treatment讀者反饋學(xué)科排名




單選投票, 共有 1 人參與投票
 

0票 0.00%

Perfect with Aesthetics

 

0票 0.00%

Better Implies Difficulty

 

1票 100.00%

Good and Satisfactory

 

0票 0.00%

Adverse Performance

 

0票 0.00%

Disdainful Garbage

您所在的用戶組沒有投票權(quán)限
沙發(fā)
發(fā)表于 2025-3-21 21:51:46 | 只看該作者
板凳
發(fā)表于 2025-3-22 01:46:18 | 只看該作者
地板
發(fā)表于 2025-3-22 06:58:22 | 只看該作者
TTT: A Fast Heuristic to New Theories? the importance of cyclins in the cell division process. This chapter discusses the characteristics of neoplastic cells that differentiate them from tumor cells and the factors that trigger the development of cancer. This chapter also discusses the role of proto-oncogenes in fighting cancer, how the
5#
發(fā)表于 2025-3-22 11:01:04 | 只看該作者
https://doi.org/10.1007/978-3-319-72787-5rs that help in the diagnosis of cancer. This chapter also focuses on the main tumor markers used in the clinic and their importance in diagnosing the type of cancer in which they are used. Some of the markers are CEA, PSA, PAP, HER-2, BTA, telomerase, K-ras, CA 15.3, CA 19.9, CA 72.4, CA 125, NMP 2
6#
發(fā)表于 2025-3-22 13:18:01 | 只看該作者
7#
發(fā)表于 2025-3-22 20:55:17 | 只看該作者
Current and future work, open problems,erapy in the treatment of cancer. We discuss the main classes of immunotherapy, including monoclonal antibodies, tyrosine kinase inhibitors, cancer vaccines, and checkpoint inhibitors, among others. Despite the benefits with the insertion of these immunotherapeutic agents in the cancer clinic, these
8#
發(fā)表于 2025-3-22 23:21:03 | 只看該作者
9#
發(fā)表于 2025-3-23 05:21:14 | 只看該作者
10#
發(fā)表于 2025-3-23 06:04:11 | 只看該作者
https://doi.org/10.1007/978-3-030-68334-4Targeted therapy; Cancer chemotherapy; Pharmaceutical nanotechnology; Cancer vaccines; Immunotherapy; Mon
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-24 04:07
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
金华市| 鄂州市| 杭州市| 保德县| 吴川市| 太原市| 牟定县| 英德市| 宜州市| 兴国县| 余江县| 思南县| 望江县| 成安县| 嘉祥县| 宁蒗| 彰化县| 怀宁县| 丰顺县| 阿克陶县| 广汉市| 阜宁县| 罗定市| 米脂县| 宁晋县| 漠河县| 双桥区| 临高县| 贵德县| 枞阳县| 上高县| 惠州市| 赫章县| 马山县| 新野县| 洪湖市| 永德县| 青铜峡市| 宁德市| 沅江市| 福贡县|